S&P/ASX 200 Index (ASX: XJO) shares are up 0.91% on Tuesday as the market continues its slow but volatile recovery.
As the chart below shows, the ASX 200 had a topsy-turvy first quarter, resulting in a net 3.87% fall in value year to date.
The benchmark index rose 4.57% in January, dropped 4.22% in February, and fell another 4.03% in March.
The ASX 200 experienced a near-official market correction when it fell by 9.43% between 14 February and 13 March.
Much of this fall was due to concerns relating to US trade tariffs.
The ASX 200 has recovered by 2.14% since 13 March.
The market received a late afternoon bump today following the Reserve Bank's decision to keep interest rates on hold, as expected.
Last month, several ASX 200 shares were downgraded to moderate or strong sell ratings by analysts on CommSec.
A strong sell rating implies investors should sell their holdings now.
A moderate sell rating suggests investors should consider trimming their positions.
CBA shares are currently trading for $152.19, up 0.83% on Tuesday.
The consensus recommendation from analysts on CommSec is a 'strong sell'.
Morgans analyst Damien Nguyen explains their sell rating on CBA shares:
While CBA remains a solid long-term business, its stretched valuation and limited near term upside make it a sell for investors seeking better risk reward opportunities in the sector.
As we reported earlier, Macquarie has an underperform rating on CBA shares with a 12-month price target of $105.
Australia's biggest ASX 200 bank share has ripped 26.8% higher over the past 12 months.
The Sigma Healthcare share price is $2.83, down 1.74% at the time of writing.
The consensus rating from analysts is a 'moderate sell'.
The ASX 200 healthcare share has rocketed 116% over the past year due to excitement over its merger with Chemist Warehouse.
The Westpac share price is $31.37, down 0.63% today.
Analysts have a consensus 'moderate sell' rating on the bank stock.
Macquarie has an underperform rating on Westpac shares with a price target of $28.
The broker said Westpac "remains expensive", trading at approximately 17x FY26's estimated price-to-earnings (P/E) ratio.
The ASX 200 bank share has lifted 20.1% over the past 12 months.
The Wesfarmers share price is $73.02, up 1.4% at the time of writing.
The consensus recommendation from analysts is a 'moderate sell'.
On The Bull, Philippe Bui of Medallion Financial Group explained their sell rating:
The industrial conglomerate has come off its highs, but was recently trading on an elevated price/earnings ratio of about 31 times that's above long term averages.
The stock seems priced for strong growth figures.
Recent half year results in fiscal year 2025 were solid, but most metrics came in at low single digits.
Although it's a defensive position, with a recent dividend yield below 3 per cent, we see much more attractive options elsewhere.
The ASX 200 consumer discretionary share is up 7.9% over the past year.
The Reece share price is $15.46, down 1.4% on Tuesday.
Analysts on CommSec have a consensus 'moderate sell' rating on the ASX 200 industrial share.
Goldman Sachs has a sell rating on Reece with a 12-month share price target of $16.80.
In a note last month, Goldman noted that Reece stock had fallen "substantially" but "continues to trade at a premium to its peer set".
The ASX 200 industrial share has fallen 44.8% over the past 12 months.
The Magellan share price is steady at $7.66 at the time of writing.
The consensus rating from analysts is a 'moderate sell'.
The ASX 200 financial share has fallen 20.4% over the past 12 months.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。